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Abstract
The proton-coupled oligopeptide transporter PEPT2 (or
SLC15A2) is the major protein involved in the reclamation of
peptide-bound amino acids and peptide-like drugs in kidney.
PEPT2 is also important in effluxing peptides and peptidomi-
metics from CSF at the choroid plexus, thereby limiting their
exposure in brain. In this study, we report a neuroprotective
role for PEPT2 in modulating the toxicity of a heme precursor,
5-aminolevulinic acid (5-ALA). Our findings demonstrate that
in PEPT2-deficient mice, 5-ALA administration results in re-
duced survivability, a worsening of neuromuscular dysfunc-
tion, and CSF concentrations of substrate that are 8–30 times
higher than that in wild-type control animals. The ability of
PEPT2 to limit 5-ALA exposure in CSF suggests that it may
also have relevance as a secondary genetic modifier of con-
ditions (such as acute hepatic porphyrias and lead poisoning)
in which 5-ALA metabolism is altered and in which 5-ALA
toxicity is important.
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Peptide transporter 2 (PEPT2) (also known as SLC15A2) is a
member of the proton-coupled oligopeptide transporter
(POT) family that is divided into two subfamilies, including
the peptide transporters (i.e. PEPT1 and PEPT2) and the
peptide/histidine transporters (i.e. PHT1 and PHT2) (Daniel
and Kottra 2004; Smith et al. 2004). PEPT2 is considered a
high-affinity transporter (i.e. with Km values in the micro-
molar range) and is abundantly expressed in the apical
membrane of kidney proximal tubule and choroid plexus
epithelial cells (Shen et al. 1999, 2004), although it is also
expressed in lung, mammary gland, and eye (Daniel and
Kottra 2004; Smith et al. 2004). In kidney, PEPT2 is the
major PEPT involved in the reclamation of peptide-bound
amino acids and peptide-like drugs (Daniel and Rubio-Aliaga
2003). In choroid plexus, PEPT2 acts as an efflux transporter,
thereby limiting the exposure of peptides (Ocheltree et al.
2005) and peptide-like drugs (Shen et al. 2007) in CSF and
brain. PEPT2 is also believed to have a role in regulating
neuropeptide homeostasis at the blood–CSF interface
(Teuscher et al. 2004; Keep and Smith 2006). Based on its
cellular localization, PEPT2 should have profound effects on
the systemic exposure and tissue distribution of peptides,
peptidomimetics, and peptide-like drugs.
In 2003, our laboratory (Shen et al. 2003) developed and
validated PEPT2-deficient mice by targeted gene disruption
in the hope of delineating the physiological, pharmacolog-
ical, and toxicological roles of this PEPT in the body.
Surprisingly, no obvious phenotypic abnormalities were
observed in PEPT2 null animals from our colonies (Shen
et al. 2003) and from that of Rubio-Aliaga et al. (2003).
Mutant PEPT2 null mice were viable and fertile, grew to
normal size and weight, and had similar blood and urine
chemistries when compared with wild-type animals. More-
over, PEPT2 null mice did not exhibit an adaptive up-
regulation in the expression level of related POT genes (such
as PEPT1, PHT1, or PHT2), at least in kidney, choroid
plexus, and brain (Ocheltree et al. 2005). However, PEPT2
had a major impact on the in vivo disposition of a model
dipeptide, glycylsarcosine (Ocheltree et al. 2005), and an
antibiotic drug, cefadroxil (Shen et al. 2007). Thus, in
PEPT2 null mice, both compounds had significantly greater
clearances (two- to threefold) as well as CSF/blood ratios
(four- to sixfold). These findings suggested that PEPT2 may
play a crucial role in influencing the pharmacologic or
toxicologic response to POT substrates.
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5-Aminolevulinic acid (5-ALA) is formed in the liver
from glycine and succinyl coenzyme A, under control of
the rate-limiting enzyme 5-ALA synthase and is a precursor
of porphyrins and heme (Anderson et al. 2001). Four types
of acute hepatic porphyria are the result of deficiencies of
specific enzymes in heme biosynthesis (i.e. 5-ALA dehy-
dratase, porphobilinogen deaminase, coproporphyrinogen
oxidase, and protoporphyrinogen oxidase), all resulting in
elevated levels of 5-ALA and porphyrin precursors (Lind-
berg et al. 1999; Anderson et al. 2001; Albers and Fink
2004). Acute porphyrias are associated with neuropsychi-
atric symptoms including mood disorders, aggressiveness,
insomnia, hallucinations, seizures, and convulsions (Ander-
son et al. 2001). The mechanisms underlying neurological
dysfunction in these disorders are poorly understood.
However, it is believed that the accumulation of 5-ALA,
originating in non-neural tissues in hepatic porphyrias, is
neurotoxic. This may also be the case in lead poisoning,
where inhibition of 5-ALA dehydratase and ferrochelatase
during heme biosynthesis results in a significant increase in
5-ALA levels (Klaassen 2006). 5-ALA has been shown to
affect the glutamatergic and GABAergic systems, inhibit
Na-K-ATPase and adenylate cyclase activities, and cause
oxidative stress (Anderson et al. 2001; Wang et al. 2005;
Adhikari et al. 2006). There have been questions raised
over whether brain (and/or CSF) concentrations of 5-ALA
reach high enough concentrations in porphyrias to induce
some of these effects (Lindberg et al. 1999). Recently,
however, Wang et al. (2005) found that extracellular 5-
ALA concentrations as low as 0.01 lmol/L could affect the
sodium channel activity in isolated rat hippocampal CA1
neurons.
5-Aminolevulinic acid is a substrate for the PEPTs with
Km values of 226–260 lmol/L in Xenopus laevis oocytes
and Pichia pastoris yeast cells expressing cloned PEPT2, and
in rat choroid plexus whole tissue where PEPT2 is highly
expressed (Döring et al. 1998; Novotny et al. 2000; Ochel-
tree et al. 2004). As 5-ALA has been implicated in the
neuropsychiatric manifestations of acute hepatic porphyrias
and lead toxicity, we hypothesized that PEPT2 might act as a
secondary genetic modifier in the sensitivity of the brain to
its toxicologic effects. If PEPT2 has a significant role in
limiting the exposure of 5-ALA in the CSF and brain, then
the wild-type mice should be better protected from challenge




[14C]5-ALA (55 mCi/mmol) and [3H]dextran (MW 70 000)
(450 mCi/g) were purchased from American Radiolabeled Chem-
icals Inc. (St Louis, MO, USA). Radiochemical purity of both
compounds was > 98% as determined by HPLC. Unlabeled 5-ALA
was obtained from Sigma-Aldrich (St Louis, MO, USA).
Animals
Studies were performed in accordance with relevant guidelines and
regulations as promulgated by the University Committee on Use and
Care of Animals at the University of Michigan, Ann Arbor. Wild-
type (PEPT2+/+) and PEPT2 null (PEPT2)/)) mice (> 99%
C57BL/6 genetic background) between 8 and 10 weeks of age
were used for these studies. Mice were kept in a temperature-
controlled environment with a 12 h light, 12 h dark cycle and
received a standard diet and water ad libitum (Unit for Laboratory
Animal Medicine, University of Michigan, Ann Arbor, MI, USA).
Gender- and weight-matched mice were used for all experiments.
Pharmacokinetics and tissue distribution of 5-ALA after
intravenous dosing
Radiolabeled 5-ALA was dissolved in normal saline and admin-
istered to the mice in aqueous solution (5 lL/g body weight).
Following sodium pentobarbital anesthesia (50 mg/kg i.p.), wild-
type and PEPT2 null mice received [14C]5-ALA (10 nmol/g body
weight) through a tail vein injection. Blood samples were collected
(20 lL) via tail nicks at 0.25, 1, 2, 5, 10, 15, 20, 30, 45, and
60 min after the intravenous bolus dose. Heparinized blood
samples were centrifuged immediately at 3000 g for 3 min to
obtain plasma. At 60 min, a CSF sample (5 lL) was taken from
the cisterna magna by puncture of the atlantooccipital membrane
with a 28-gauge needle. The mouse was immediately decapitated
and tissue samples from choroid plexuses (i.e. lateral and fourth
ventricles), cerebral cortex, kidney, liver, eye, lung, heart, spleen,
small and large intestines, skeletal muscle, ovary, and testes were
collected. Kidney was processed as intact tissue for one kidney
and as cortex, outer medulla (outer and inner stripes), and inner
medulla for the other kidney. [3H]Dextran (1 lCi/mouse) was
administered intravenously 5 min prior to harvesting the tissues so
that [14C]5-ALA tissue concentrations could be corrected for the
vascular space. Samples were blotted dry, weighed, and then
solubilized with 0.4 mL of 1 mol/L hyamine hydroxide, as
described by the manufacturer (ICN, Irvine, CA, USA). Cytoscint
(6 mL) liquid scintillation cocktail (ICN) was added to each
sample (i.e. digested tissue, CSF, and plasma), and radioactivity
was measured by a dual-channel liquid scintillation counter
(Beckman LS 3801; Beckman Coulter Inc., Fullerton, CA,
USA). Corrected tissue concentrations of 5-ALA (Ctiss, corr,
nmol/g wet tissue) were calculated as (Keep et al. 1999; Ocheltree
et al. 2005): Ctiss, corr = Ctiss ) DS · Cb, where Ctiss is the
uncorrected 5-ALA tissue concentration (nmol/g), DS is the
dextran space (i.e. blood vascular space) in the tissue (mL/g),
and Cb is the 5-ALA blood concentration (nmol/mL). Plasma
concentration–time curves were fit to a two-compartment model
with a weighting factor of unity using WinNonlin (version 5.0.1;
Pharsight Inc., Mountain View, CA, USA) and pharmacokinetic
parameters (see Table 1) were determined by standard methods.
The quality of fit was determined by evaluating the standard error
of parameter estimates, by visual inspection of the residual plots,
and by the coefficient of determination (r2). Plasma and tissue
concentrations of 5-ALA (expressed in micromolar) were calcu-
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lated by dividing the sample measurements (dpm/mL) by the
specific activity of the radiolabeled compound.
Toxicological studies after subcutaneous dosing of 5-ALA
Dose-ranging studies were initially performed with unlabeled 5-
ALA (i.e. subcutaneous doses escalated daily from 500 to 5000 mg/
kg) in wild-type and PEPT2 null mice in an attempt to discriminate
between genotypes in their survivability. Based on these pilot
studies, 24-h survival experiments were subsequently performed in
mice after a single 4000 mg/kg dose of 5-ALA, administered
subcutaneously (injection volume of 0.2 mL saline), and the results
analyzed using a Kaplan–Meier estimator.
Neuromuscular studies after subcutaneous dosing of 5-ALA
Serial measurements were made on a rotating rod (3.5 cm diameter,
5 rpm velocity plus 0.1 rpm/s), where altered balance times were
used as a measure of neurological dysfunction to unlabeled 5-ALA
in mice. In these experiments, balance times were evaluated in wild-
type and PEPT2 null mice, 30 min after subcutaneous dosing
(injection volume of 0.2 mL saline) of 500 mg/kg 5-ALA given
daily for 7 days or 100 mg/kg 5-ALA given daily for 30 days. This
study design was intended to probe the modulating effect of PEPT2
on 5-ALA neurotoxicity under chronic conditions and at plasma
concentrations that would be more reflective of those levels actually
observed in patients with hepatic porphyria.
Systemic exposure and brain distribution studies after
subcutaneous dosing of 5-ALA
Following sodium pentobarbital anesthesia (50 mg/kg i.p.), wild-
type and PEPT2 null mice received 100 mg/kg of [14C]5-ALA as a
subcutaneous dose (injection volume of 0.2 mL saline). Blood
samples were obtained (20 lL) via tail nicks at 5, 10, 30, 60, 90,
120, 180, and 240 min after the dose. Heparinized blood samples
were centrifuged immediately at 3000 g for 3 min to obtain plasma.
In some animals, CSF (5 lL) and choroid plexus samples were
obtained at 30 and 240 min. [14C]5-ALA tissue concentrations were
corrected for vascular space by administering [3H]dextran (0.1 lCi/
mouse) intravenously 2 min prior to harvesting the tissues. Samples
were then collected, processed, and analyzed, as described before. It
should be noted that normal endogenous levels of 5-ALA (e.g. about
0.1 lmol/L in plasma and 0.02 lmol/L in CSF) (Gorchein and
Webber 1987) are substantially lower than the concentrations
generated by exogenously administered [14C]5-ALA.
Statistics
Data are expressed as mean ± SE. Statistical comparisons between
wild-type and PEPT2 null mice were performed by a two sample t-
test (GraphPad Prism, version 3.0; GraphPad Software Inc., San
Diego, CA, USA) in which a probability of p £ 0.05 was considered
statistically significant. Statistical differences between multiple
treatment groups (in the same genotype) were determined by
analysis of variance and pairwise comparisons with the control
group were made using Dunnett’s test. A two-way ANOVA was
performed to simultaneously evaluate the effect of two factors (i.e.
time and genotype) on a variable.
Results
Pharmacokinetic and tissue distribution studies after
intravenous dosing
A preliminary study was performed with intravenous dosing
of [14C]5-ALA in order to probe whether or not PEPT2
expression would influence the pharmacokinetics and tissue
distribution of this substrate. As shown in Fig. 1a, the plasma
concentrations of 5-ALA were substantially lower in PEPT2
null mice when compared with wild-type control animals.
The reduced systemic exposure (i.e. area under the plasma
concentration–time curve) reflects the greater clearance of 5-
ALA in animals deficient in renal PEPT2 (Table 1). Volume
of distribution terms (i.e. V1 and Vdss) were not significantly
different between genotypes, but other measures of a faster
elimination of 5-ALA from the body were observed in
knockout mice (i.e. K10, t1/2, and mean residence time;
Table 1). Differences are also evident when one compares
the tissue distribution of 5-ALA between PEPT2+/+ and
PEPT2)/) animals. As observed in Fig. 1b 5-ALA concen-
trations are significantly lower in the choroid plexus, cerebral
cortex, kidney (including renal cortex and outer medulla),
eye, and blood of PEPT2 null mice. In contrast to tissue and
blood, PEPT2)/) mice had a fivefold greater concentration
of 5-ALA in CSF and an eightfold greater CSF/blood
concentration ratio. This finding is consistent with the action
of PEPT2 in effluxing POT substrates from the CSF into
choroid plexus epithelial cells. As a result, PEPT2 may have
a significant impact on 5-ALA distribution in brain extra-
cellular fluid and, presumably, on its neurotoxicity. Based on
these results, subsequent experiments were performed with
5-ALA after subcutaneous dosing, a route that would
facilitate the chronic dosing of substrate (see below).
Table 1 Pharmacokinetics of 5-ALA plasma concentrations in
PEPT2+/+ and PEPT2)/) mice after a 10 nmol/g intravenous bolus
dose
Parameter PEPT2+/+ PEPT2)/)
V1 (mL) 3.45 (0.04) 2.89 (0.09)
Vdss (mL) 10.4 (3.1) 7.39 (1.30)
AUC (lmol · min/L) 617 (39) 362 (30)**
CL (mL/min) 0.331 (0.097) 0.587 (0.067)**
K10 (min
)1) 0.106 (0.015) 0.229 (0.036)*
t1/2 (min) 25.8 (10.2) 10.5 (2.4)*
MRT (min) 32.8 (12.1) 12.8 (2.9)*
r2 0.963 (0.012) 0.981 (0.009)
V1 is the volume of the central compartment, Vdss is the volume of
distribution steady state, AUC is the area under the plasma concen-
tration–time curve, CL is the total plasma clearance, K10 is the elimi-
nation rate constant from the central compartment, t1/2 is the terminal
half-life, MRT is the mean residence time, and r2 is the coefficient of
determination. Data are represented as mean (±SE) (n = 6). *p < 0.05
and **p < 0.01 compared with PEPT2+/+ (wild-type) mice. 5-ALA,
5-aminolevulinic acid; PEPT2, peptide transporter 2.
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Toxicological studies after subcutaneous dosing
Figure 2 demonstrates that PEPT2 had a major impact on the
ability of PEPT2 null mice to survive the toxic insult of a
high single dose of 5-ALA (4000 mg/kg). While the time at
which 50% of the animals died (i.e. LT50) was 21 h in
PEPT2-competent mice, the LT50 for animals lacking the
PEPT2 gene was only 4 h (p < 0.001). This finding provides
strong evidence that PEPT2 confers a neuroprotective
advantage in those mice containing PEPT2 protein in brain.
Neuromuscular studies after subcutaneous dosing
Further evidence for a neuroprotective role of PEPT2 is
demonstrated in Fig. 3. Under chronic dosing conditions of
500 mg/kg 5-ALA given daily for 7 days, PEPT2+/+ mice
showed no sign of any altered ability to maintain balance on
a rotating beam (i.e. rotary rod test) (Fig. 3a). However, the
rotary rod times of PEPT2-deficient mice were progressively
reduced in response to 5-ALA administration. In particular,
neuromuscular dysfunction was observed after 4 days of 5-
ALA dosing, and balance times were reduced to 58% of
control values at 7 days. This finding was even more
convincing when chronic dosing conditions of 100 mg/kg
5-ALA given daily for 30 days were examined (Fig. 3b). In
that study, by 30 days, PEPT2+/+ mice had balance times
that were 91% of control values while PEPT2)/) mice had
balance times that were only 60% of control values (i.e. at
day 0). Moreover, there were highly significant correlations
as a function of time and genotype (p < 0.001 for both
factors).
Systemic exposure and brain distribution studies after
subcutaneous dosing
As shown in Fig. 4, there is little difference in the systemic
exposure of 5-ALA (100 mg/kg) in wild-type and PEPT2
null mice after subcutaneous dosing. Peak plasma concen-
trations occurred at 30 min and almost all the 5-ALA was
eliminated from the body at 240 min. As a result, accumu-
lation of 5-ALA is not expected when dosed once a day over
7 days or even 30 days. Although the plasma concentrations
were similar between PEPT2+/+ and PEPT2)/) mice, CSF
concentrations of 5-ALA were eight- and 30-fold greater at
30 min (p < 0.001) and 240 min (p < 0.001), respectively, in
PEPT2 null mice (Fig. 5a). These differences reflected the
loss of PEPT2 in apical membranes of choroid plexus
epithelial cells and, as a result, 5-ALA concentrations in the
choroid plexus whole tissue of PEPT2)/) mice were 8% and
17% of the values in PEPT2+/+ animals at 30 min
(p < 0.001) and 240 min (p < 0.01), respectively (Fig. 5b).
Fig. 1 Disposition of 5-aminolevulinic acid (5-ALA) in wild-type and
peptide transporter 2 null mice following a 10 nmol/g intravenous bolus
dose. (a) Plasma concentration-time profiles of 5-ALA. Data are ex-
pressed as mean ± SE (n = 6 per genotype). (b) Tissue (nmol/g), CSF
(micromolar), and blood (micromolar) concentrations of 5-ALA, 60 min
after dosing. Data are expressed as mean ± SE (n = 6 per genotype).
*p < 0.05, **p < 0.01, and ***p < 0.001 compared with PEPT2+/+
(wild-type) mice. CP is the choroid plexus, C. Cortex is the cerebral
cortex, O. Medulla is the outer medulla, I. Medulla is the inner medulla,
S. Intestine is the small intestine, L. Intestine is the large intestine, and
Sk. Muscle is the skeletal muscle.
Fig. 2 Kaplan–Meier survival curves in wild-type and peptide trans-
porter 2 null mice following a single 4000 mg/kg subcutaneous dose of
5-aminolevulinc acid. LT50 is the time at which one-half the animals
die (n = 12 per genotype).
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The differences in CSF and choroid plexus concentrations of
5-ALA were not the result of differences in plasma concen-
tration as little or no changes were observed (i.e. less than
25%; Fig. 5c).
Discussion
Our findings are novel in establishing, for the first time, a
neuroprotective phenotype for the POT family member
PEPT2. Specifically, we demonstrate: (i) that survivability is
reduced in PEPT2-deficient mice after high-dose acute
administration of 5-ALA, (ii) that neuromuscular function
is worsened in PEPT2-deficient mice after chronic dosing of
5-ALA, and (iii) that the pharmacokinetic profile, as best
reflected by the 8–30 times higher CSF levels of 5-ALA in
PEPT2)/) mice, is consistent with the pharmacodynamic
observations. Moreover, the results are clinically relevant as
the 5-ALA plasma levels in this study (i.e. about 23 lmol/L;
calculated as area under the plasma concentration–time
curve/24 h) are similar to the plasma concentrations of 5-
ALA observed in patients during acute attacks of porphyria
(i.e. 2–13 lmol/L) (Lindberg et al. 1999), supporting the
hypothesis that 5-ALA is the neurotoxic agent in porphyrias.
Of all the tissues examined, CSF was the only compartment
that had higher concentrations of 5-ALA in PEPT2-deficient
mice when compared with wild-type animals. This suggests
that the greater toxicity of 5-ALA in PEPT2)/) mice is
because of changes in CSF (and presumably brain extracel-
lular fluid) concentrations.
Accumulation of the porphyrin precursors, 5-ALA and/or
porphobilinogen, have been implicated as causes of the
neuropsychiatric symptoms that occur in acute hepatic
porphyrias and lead toxicity (Lindberg et al. 1999; Anderson
et al. 2001; Albers and Fink 2004; Klaassen 2006). A
number of mechanisms (which may be interrelated) have
been proposed by which 5-ALA may affect CNS function.
These include effects on the glutamatergic and GABAergic
systems, inhibition of Na-K-ATPase and adenylate cyclase
activities, and oxidative stress (Anderson et al. 2001; Wang
et al. 2005; Adhikari et al. 2006). However, many, but not
all (Wang et al. 2005), studies have used very high
concentrations of 5-ALA (often in the millimolar range) that
may not be relevant to porphyrias and Edwards et al. (1984)
found that acute administration of 5-ALA by subcutaneous or
intraperitoneal injection does not significantly affect noci-
ception, CNS excitability, motor coordination, grip, and
cardiovascular function in rodents. In the latter study, the
authors noted that their results were not consistent with the
evidence obtained from in vitro studies which suggested that
Fig. 3 Rotary rod test in wild-type and peptide transporter 2 (PEPT2)
null mice. (a) 5-Aminolevulic acid was administered daily at 500 mg/kg
subcutaneous doses for 7 days, and the balance times were mea-
sured pre-dose and 30 min after dosing on days 1, 4, and 7. Data are
expressed as mean ± SE (n = 4–8 per genotype). *p < 0.05, and
**p < 0.01 compared with the pre-dose control group of PEPT2 null
mice. p < 0.05 compared with PEPT2+/+ (wild-type) mice on the
same day. (b) 5-aminolevulinic acid was administered daily at 100 mg/
kg subcutaneous doses for 30 days, and the effect was measured pre-
dose and 30 min after dosing on days 1, 4, 8, 11, 15, 18, 22, 25, and
29. Data are expressed as mean ± SE (n = 8 per genotype).
Fig. 4 Plasma concentration–time profiles of 5-aminolevulinic acid (5-
ALA) in wild-type and peptide transporter 2 null mice following a
100 mg/kg subcutaneous dose. Data are expressed as mean ± SE
(n = 5 per genotype).
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5-ALA has significant neuropharmacological activity. They
suggested a need for chronic studies to better understand the
relationship between 5-ALA doses and neurotoxicity.
Adhikari et al. (2006) recently found that chronic adminis-
tration of low doses of 5-ALA (40 mg/kg in rat) reduced
GABAergic receptor density in the brain although they did
not report any behavioral data. In our current study, we found
that chronic administration of a low dose of 5-ALA (100 mg/
kg) for 30 days, which produced pathophysiologically rele-
vant 5-ALA concentrations, could induce behavioral deficits
in PEPT2 null mice where the lack of the transporter lead to
increased CSF concentrations. It is unlikely that these effects
were influenced by a compensatory response to PEPT2 gene
disruption as previous studies have indicated that the null
mice do not exhibit altered expression levels of related POT
genes (Rubio-Aliaga et al. 2003; Ocheltree et al. 2005; Frey
et al. 2007).
Targeted gene replacement has allowed scientists to learn
more about the physiological, pharmacological, and patho-
logical role of a particular gene product in the body
(Capecchi 1994; Elmquist and Miller 2001). However,
disruption of a specific gene does not always result in
phenotypical abnormalities, especially with respect to knock-
ing out transporter proteins. For example, it was by pure
serendipity that mice lacking the multidrug resistance gene
1a were found to be extremely sensitive to the anthelmintic
drug, ivermectin (Schinkel et al. 1994). During the typical
spraying of animals to treat mite infestation, a number of
mice died with paralytic symptoms. Apparently, loss of the
gene product, p-glycoprotein, at the blood–brain barrier
allowed this normally safe pesticide to reach levels in the
brain that were 90 times greater than that observed in wild-
type mice. Another example involves the breast cancer
resistance protein 1 in which null mice did not demonstrate
phenotypic aberrations under standard housing conditions
(Jonker et al. 2002). However, a few mice housed on the top
shelf, closest to the fluorescent light source and being fed one
particular batch of food containing alfalfa leaf concentrate,
developed severe necrotic ear lesions. In this case, high
levels of pheophorbide a, a phototoxic porphyrin catabolite
of chlorophyll, was formed during the storage of alfalfa. Both
examples point to the fact that, on occasion, a phenotypic
abnormality is not observed until the mice are challenged in a
certain manner. With respect to our PEPT2 knockout mice,
chronic dosing of 5-ALA (or a very high single dose) was
necessary in order to observe a toxicologic phenotype. This
result suggests that human subjects with a reduced functional
activity or expression of PEPT2 in brain may be more
sensitive to the neurotoxic effects of POT substrates such as
5-ALA.
It should be noted that, as PEPT2-mediated transport is
hydrogen ion dependent, functional activity may also change
in disease states where CSF pH is altered. For example,
respiratory (unlike metabolic) acidosis/alkalosis can cause
marked changes in CSF pH (Kazemi and Johnson 1986), and
CSF pH levels as low as 6.59 have been recorded in patients
with traumatic injury as a result of cerebral ischemia and
Fig. 5 Biological concentrations of 5-aminolevulinic acid (5-ALA) in
wild-type and peptide transporter 2 (PEPT2) null mice, 30 and 240 min
after a 100 mg/kg subcutaneous dose. (a) 5-ALA concentrations in
CSF. Data are expressed as mean ± SE (n = 5 per genotype).
***p < 0.001 compared with PEPT2+/+ (wild-type) mice at the same
sampling time. (b) 5-ALA concentrations in choroid plexus. Data are
expressed as mean ± SE (n = 5 per genotype). **p < 0.01 and
***p < 0.001 compared with PEPT2+/+ (wild-type) mice at the same
sampling time. (c) 5-ALA concentrations in plasma. Data are ex-
pressed as mean ± SE (n = 10 per genotype). *p < 0.05 compared
with PEPT2+/+ (wild-type) mice at the same sampling time.
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increases in CSF lactate, pyruvate, and pCO2 (Shiogai et al.
1999). Normal pH in the CSF is 7.3 (Smith et al. 2004).
Numerous single nucleotide polymorphisms have been
reported for the SCL15A2 gene in humans (Pinsonneault
et al. 2004; Terada et al. 2004). In the first study (Terada
et al. 2004), transport activity of genetic variant Arg57His
was completely abolished when transiently expressed in both
human embryonic kidney 293 cells and Xenopus laevis
oocytes. The functional impairment by this rare non-synon-
ymous polymorphism (i.e. hPEPT2 R57H) occurred in spite
of a conserved protein expression at the cell plasma
membrane. In the second study (Pinsonneault et al. 2004),
a haplotype analysis revealed two main hPEPT2 variants (i.e.
hPEPT2*1 and *2), with several phased amino acid substi-
tutions, that were present in substantial frequencies in all
ethnic groups tested. When expressed in Chinese Hamster
Ovary cells, the Km values of glycylsarcosine differed
significantly (83 lmol/L vs. 233 lmol/L for hPEPT2*1 vs.
*2, respectively) as did their sensitivity to proton/substrate
symport. These results indicate that polymorphisms in the
gene encoding hPEPT2 can alter peptide/mimetic transport,
be it from exogenous or endogenous sources. Whether or not
genetic polymorphisms of PEPT2 are present in patients with
acute hepatic porphyrias or lead poisoning is currently
unknown. However, there are a variety of mutations that
markedly reduce the activity of specific enzymes in heme
biosynthesis (Anderson et al. 2001) and, in this context, it is
possible that PEPT2 may act as a secondary genetic modifier
in making these patients more sensitive to the pharmacologic
or toxicologic effects of POT substrates such as 5-ALA.
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